REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026
MWN-AI** Summary
Kirby McInerney LLP is urging investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) who experienced significant losses to take action by the upcoming deadline of April 21, 2026, to apply for the role of lead plaintiff in an ongoing federal securities class action lawsuit. The lead plaintiff will represent the interests of the class and play a crucial role in deciding the course of the litigation.
The lawsuit pertains to investors who acquired Corcept securities between October 31, 2024, and December 30, 2025. Allegations center around the company’s misleading representations regarding the clinical trials for its drug, relacorilant, intended to treat hypercortisolism. Corcept claimed their trials provided "powerful support" for their New Drug Application (NDA) to the FDA and asserted confidence in receiving approval. However, evidence suggests that the FDA had raised serious concerns about the adequacy of the clinical data supporting the NDA, which contradicted the company's public assurances.
The situation escalated when, on December 31, 2025, Corcept disclosed that the FDA had issued a Complete Response Letter (CRL), indicating it could not assess the benefits and risks without further evidence of relacorilant's effectiveness. Following this announcement, Corcept’s stock plummeted by over 50%, from $70.20 to $34.80.
The CRL's publication in January 2026 reinforced the critique of Corcept's application, which further impacted share prices. Investors with losses are encouraged to contact Lauren Molinaro of Kirby McInerney LLP to discuss their rights and potential actions regarding this class action lawsuit.
MWN-AI** Analysis
Corcept Therapeutics Incorporated (NASDAQ: CORT) investors facing significant losses have a critical deadline approaching on April 21, 2026, to seek lead plaintiff status in a federal securities class-action lawsuit. This legal action arises from allegations that the company misrepresented the likelihood of FDA approval for its drug, relacorilant, during the Class Period from October 31, 2024, to December 30, 2025. Allegedly, Corcept conveyed an overly optimistic view of its NDA submission process, neglecting to disclose known risks related to the adequacy of clinical trial data.
Following a Complete Response Letter (CRL) from the FDA on December 31, 2025, which highlighted concerns regarding the submitted data's sufficiency for demonstrating relacorilant's efficacy, the company's share price plummeted by over 50% in one day. Subsequent disclosures indicated that the FDA had informed Corcept of its concerns well before the NDA submission, raising serious questions about the company’s transparency.
For investors, immediate action is advisable. Engaging with legal counsel through firms like Kirby McInerney LLP can provide insight into potential recovery avenues. Acting by the April 21 deadline not only allows individuals to apply for lead plaintiff status—which could influence litigation strategy—but also positions them to participate fully in any settlements that arise from the lawsuit.
Investors must assess their eligibility and consider coordinating with others affected by the stock's decline. Monitoring further updates on the FDA's stance and Corcept's responses can help gauge the company's future prospects. In the evolving landscape of biotech stocks, transparency and regulatory compliance remain paramount; hence, staying informed and responding proactively is essential for protecting legal and financial interests in Corcept's ongoing situation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.
If you purchased or otherwise acquired Corcept securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com , or fill out the form below, to discuss your rights or interests.
[ CONTACT THE FIRM IF YOU SUFFERED A LOSS ]
What Is The Lawsuit About?
The lawsuit has been filed on behalf of investors who purchased securities during the period of October 31, 2024 through December 30, 2025, inclusive (“the Class Period”). The lawsuit alleges that the Company represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. The Company also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the Class Period, Corcept repeatedly told investors that “relacorilant is approaching approval.” In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the relacorilant NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA would not be approved.
On December 31, 2025, Corcept revealed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” On this news, the price of Corcept shares declined by $35.40 per share, or approximately 50.4%, from $70.20 per share on December 30, 2025 to close at $34.80 on December 31, 2025.
On January 30, 2026, after the end of the Class Period, the FDA published a redacted copy of the CRL. The CRL detailed the FDA’s concerns with the relacorilant NDA, including concerns that the clinical studies that were submitted as part of the NDA were not sufficient evidence of relacorilant’s efficacy for the proposed indication. The CRL also noted that, during pre-submission meetings, the FDA informed Corcept “on several occasions” of its “concerns about the adequacy of the clinical development program,” and had warned the Company “to expect significant review issues,” if it submitted the application. On this news, the price of Corcept shares declined by $4.74 per share, or approximately 10.6%, from $44.61 per share on January 29, 2026 to close at $39.87 on January 30, 2026.
[ CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION ]
What Should I Do?
If you purchased or otherwise acquired Corcept securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com , or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[ WHAT IS A SECURITIES CLASS ACTION? ]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website .
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260310628815/en/
Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com
FAQ**
What specific allegations are being made against Corcept Therapeutics Incorporated (CORT) regarding the accuracy of their statements about the relacorilant NDA during the Class Period?
How might the outcome of this securities class action impact the future stock performance of Corcept Therapeutics Incorporated (CORT) based on investor sentiment and market perception?
What steps should investors who purchased Corcept Therapeutics Incorporated (CORT) securities during the Class Period take to protect their rights and potentially participate in the class action?
In light of the FDA's Complete Response Letter, what risks do current and potential investors in Corcept Therapeutics Incorporated (CORT) need to consider before making investment decisions?
**MWN-AI FAQ is based on asking OpenAI questions about Corcept Therapeutics Incorporated (NASDAQ: CORT).
NASDAQ: CORT
CORT Trading
0.75% G/L:
$33.71 Last:
300,393 Volume:
$33.47 Open:
